Hims & Hers Health Stock Stumbles After Earnings. Here's Why. -- Barrons.com

Dow Jones

Aug 05, 2025

By Liz Moyer

Hims & Hers Health, a telehealth platform that sells knock offs of popular weight loss drugs, sank in after-hours trading after missing expectations on quarterly earnings and revenue.

The stock was down 12% at $55.68 in after-hours trading Monday. It is up 162% so far this year, according to Dow Jones Market Data.

The company reported earnings of 17 cents a share and revenue of $544.8 million, which is up more than 72% from a year ago. Analysts tracked by FactSet were even more optimistic, however. The consensus revenue forecast was $551.7 million.

Hims & Hers also issued guidance that was in line with expectations. It sees third quarter revenue in a range of $570 million to $590 million a share. Its guidance for the full year 2025 hasn't changed: Revenue of $2.3 billion to $2.4 billion and earnings before interest, taxes, depreciation, and appreciation of $295 million to $335 million.

This is a developing story. Check back here for details.

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

August 04, 2025 17:21 ET (21:21 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2557337854"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557337854\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557337854?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-05 05:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557337854","market":"nz","top_or_hot":-1,"title":"Hims & Hers Health Stock Stumbles After Earnings. Here's Why. -- Barrons.com","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Liz Moyer \n</p>\n<p>\n  Hims &amp; Hers Health, a telehealth platform that sells knock offs of popular weight loss drugs, sank in after-hours trading after missing expectations on quarterly earnings and revenue. \n</p>\n<p>\n     The stock was down 12% at $55.68 in after-hours trading Monday. It is up 162% so far this year, according to Dow Jones Market Data. \n</p>\n<p>\n     The company reported earnings of 17 cents a share and revenue of $544.8 million, which is up more than 72% from a year ago. Analysts tracked by FactSet were even more optimistic, however. The consensus revenue forecast was $551.7 million. \n</p>\n<p>\n     Hims &amp; Hers also issued guidance that was in line with expectations. It sees third quarter revenue in a range of $570 million to $590 million a share. Its guidance for the full year 2025 hasn't changed: Revenue of $2.3 billion to $2.4 billion and earnings before interest, taxes, depreciation, and appreciation of $295 million to $335 million. \n</p>\n<p>\n     This is a developing story. Check back here for details. \n</p>\n<p>\n     This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 04, 2025 17:21 ET (21:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Health Stock Stumbles After Earnings. Here's Why. -- Barrons.com</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Health Stock Stumbles After Earnings. Here's Why. -- Barrons.com\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-05 05:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Liz Moyer \n</p>\n<p>\n  Hims &amp; Hers Health, a telehealth platform that sells knock offs of popular weight loss drugs, sank in after-hours trading after missing expectations on quarterly earnings and revenue. \n</p>\n<p>\n     The stock was down 12% at $55.68 in after-hours trading Monday. It is up 162% so far this year, according to Dow Jones Market Data. \n</p>\n<p>\n     The company reported earnings of 17 cents a share and revenue of $544.8 million, which is up more than 72% from a year ago. Analysts tracked by FactSet were even more optimistic, however. The consensus revenue forecast was $551.7 million. \n</p>\n<p>\n     Hims &amp; Hers also issued guidance that was in line with expectations. It sees third quarter revenue in a range of $570 million to $590 million a share. Its guidance for the full year 2025 hasn't changed: Revenue of $2.3 billion to $2.4 billion and earnings before interest, taxes, depreciation, and appreciation of $295 million to $335 million. \n</p>\n<p>\n     This is a developing story. Check back here for details. \n</p>\n<p>\n     This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 04, 2025 17:21 ET (21:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2557337854","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557337854","pubTimestamp":1754342460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Hims & Hers Health, a telehealth platform that sells knock offs of popular weight loss drugs, sank in after-hours trading after missing expectations on quarterly earnings and revenue.The stock was down 12% at $55.68 in after-hours trading Monday. It is up 162% so far this year, according to Dow Jones Market Data.The company reported earnings of 17 cents a share and revenue of $544.8 million, which is up more than 72% from a year ago. Analysts tracked by FactSet were even more optimistic, however. The consensus revenue forecast was $551.7 million.Hims & Hers also issued guidance that was in line with expectations. It sees third quarter revenue in a range of $570 million to $590 million a share. Its guidance for the full year 2025 hasn't changed: Revenue of $2.3 billion to $2.4 billion and earnings before interest, taxes, depreciation, and appreciation of $295 million to $335 million.This is a developing story. Check back here for details.This content was created by Barron's, which is op","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc.","FDS":"辉盛研究系统"},"translate_title":"Hims&Hers Health股票在盈利后下跌。原因如下。——Barrons.com","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FDS":0.9,"HIMS":0.9},"content_text":"By Liz Moyer \n\n\n  Hims & Hers Health, a telehealth platform that sells knock offs of popular weight loss drugs, sank in after-hours trading after missing expectations on quarterly earnings and revenue. \n\n\n     The stock was down 12% at $55.68 in after-hours trading Monday. It is up 162% so far this year, according to Dow Jones Market Data. \n\n\n     The company reported earnings of 17 cents a share and revenue of $544.8 million, which is up more than 72% from a year ago. Analysts tracked by FactSet were even more optimistic, however. The consensus revenue forecast was $551.7 million. \n\n\n     Hims & Hers also issued guidance that was in line with expectations. It sees third quarter revenue in a range of $570 million to $590 million a share. Its guidance for the full year 2025 hasn't changed: Revenue of $2.3 billion to $2.4 billion and earnings before interest, taxes, depreciation, and appreciation of $295 million to $335 million. \n\n\n     This is a developing story. Check back here for details. \n\n\n     This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 04, 2025 17:21 ET (21:21 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}